Cholesterol-modifying drugs in COVID-19

Infection with severe acute respiratory syndrom coronavirus 2 (SARS-CoV-2) is more likely to lead to poor outcomes in the elderly and those with cardiovascular disease, obesity or metabolic syndrome. Here, we consider mechanisms by which dyslipidaemia and the use of cholesterol-modifying drugs could...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Nathalie M, Wing, Peter A C, McKeating, Jane A, Maini, Mala K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337782/
https://www.ncbi.nlm.nih.gov/pubmed/33047740
http://dx.doi.org/10.1093/oxfimm/iqaa001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337782/
https://www.ncbi.nlm.nih.gov/pubmed/33047740
http://dx.doi.org/10.1093/oxfimm/iqaa001

Ejemplares similares